Dianthus Therapeutics, Inc. /DE/ Shareholders' Equity
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Shareholders' Equity of $1.17 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.17B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.20B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $493.40M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $546.45M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $1.17B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $1.20B 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $493.40M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $546.45M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $303.08M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $328.61M 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $352.48M 10-Q · filed 2026-08-04 | |
| 2024-09-30 | $337.90M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $358.22M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $372.69M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $168.87M 10-K · filed 2026-03-09 | |
| 2023-09-30 | $178.38M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$61.46M 10-Q · filed 2024-11-07 | $74.60M 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$50.82M 10-Q · filed 2024-11-07 | $77.46M 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$44.37M 10-K · filed 2025-03-11 | $105.96M 10-K · filed 2023-03-23 |
| 2022-09-30 | -$34.75M 10-Q · filed 2023-11-09 | $124.03M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$27.48M 10-Q · filed 2023-11-09 | $135.68M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$22.07M 10-Q · filed 2023-11-09 | $151.19M 10-Q · filed 2022-05-16 |
| 2021-12-31 | -$17.25M 10-K · filed 2024-03-21 | $172.67M 10-K · filed 2022-03-08 |
| 2021-09-30 | $189.69M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $202.89M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $129.06M 10-Q · filed 2022-08-04 | |
| 2020-12-31 | -$4.20M 8-K · filed 2023-12-21 | $143.91M 10-K · filed 2021-03-03 |
| 2020-09-30 | $158.57M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $173.91M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $125.40M 10-Q · filed 2021-08-05 | |
| 2019-12-31 | $141.19M 10-K · filed 2022-03-08 | |
| 2019-09-30 | $161.53M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $179.56M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $134.00M 10-Q · filed 2020-08-06 | |
| 2018-12-31 | $145.65M 10-K · filed 2021-03-03 | |
| 2018-09-30 | $159.78M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $172.22M 10-Q · filed 2019-11-13 | |
| 2018-03-31 | -$51.85M 10-Q · filed 2019-08-08 | |
| 2017-12-31 | -$42.12M 10-K · filed 2020-03-03 | |
| 2016-12-31 | -$8.87M 10-K · filed 2020-03-03 | |
| 2015-12-31 | -$289.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |